Podcasts about Bergman

Reaction Monday is here! The crew celebrates the Knicks' NBA title win, with D'Marco reminding everyone he was the only one who picked them to win it all. They also debate whether Victor Wembanyama is becoming the NBA's next villain. Plus, Travis and Marcas swap baseball bucket-list stories after Mookie Betts' costly error spoiled Yoshinobu Yamamoto's perfect game bid, and Marcas steps in for Bergman on First Pitch. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Kappy, Geeter, and Beto react to the Knicks' historic 29-point comeback win over the Spurs in Game 4 of the NBA Finals, the biggest comeback in Finals history. The guys debate when they thought the game was over, whether the Knicks won it or the Spurs choked it away, and De'Aaron Fox's late-game blunder. They break down OG Anunoby's heroics, Mitchell Robinson roughing up Wemby, and Mike Brown's coaching edge over Mitch Johnson. Bergman joins for the Blue Review as the Dodgers blow a 6-1 lead to the Pirates despite a strong Ohtani start and a Ryan Ward grand slam. Plus, the World Cup kicks off today with Mexico vs. South Africa. Learn more about your ad choices. Visit podcastchoices.com/adchoices

To cineastes of the 20th century, Ingmar Bergman was a fixture on the Mount Rushmore of World Cinema. His cultural presence receded in the decades following his death but Gen Z interest in his films, driven by streaming and Letterboxd, is suddenly on the rise. We couldn't wait to pick one of his most challenging movies to see how it plays to a younger audience. Persona (1966), made smack-dab in the middle of Bergman's career, has delighted and perplexed audiences from the day it was released. Some of the issues it tackles — identity, motherhood, sexuality — are perennial. Others -- Jungian duality and the artificiality of filmmaking — seem ripe for a comeback. Hearing different generations of film lovers grapple with this masterpiece illuminates how our culture has changed and what continues to endure. Listen in for the surprising results.   Hosts: Mark Netter & David Tausik  Panelists:  Guy Lewis, Kylee LaRue, Olive Goldberg & Brennan Guntang An ElectraCast Production  Trailer: https://www.youtube.com/watch?v=YEfJopPIbQg&t=163s Wikipedia: https://en.wikipedia.org/wiki/Persona_(1966_film) IMDB: https://www.imdb.com/title/tt0060827/ Rotten Tomatoes: https://www.rottentomatoes.com/m/persona Learn more about your ad choices. Visit megaphone.fm/adchoices

Time for Sports Graffiti! Mason and Ireland discuss athletes taking jersey numbers of players that are already on the team. The crew is joined by special guest ESPN's Rich Eisen! The guys dive into the idea of College Sports being ‘broken.' What did Notre Dame's AD have to say about a ‘Super League'? Bergman drops into the studio for another ‘Boys in Blue Report!' Learn more about your ad choices. Visit podcastchoices.com/adchoices

Sedano's voice is recovering on prednisone after working NBA Finals Game 1 on ESPN Radio amidst his 10-day dry streak past a 2 am Charles Barkley rooftop session. On the game: the Knicks erased a 14-point deficit to win by 10, with Jalen Brunson owning the fourth despite an injury and Karl-Anthony Towns huge early, while Wemby went cold, De'Aaron Fox melted down late, and Sedano still picked the Spurs to win the series. Bergman's Three Things centered on Shohei Ohtani's historic two-way run, Kyle Tucker's first homer in a month, and a scuffling Mookie Betts. Michelle Smallmon dropped by to crown the Rams the NFL's new villains after the Myles Garrett deal. Plus the crew marveled at how it's cheaper to fly first class to San Antonio than buy comparable seats at MSG. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The digital hour opens with the crew hyping tomorrow's live broadcast from Sea World San Diego, Kap angling to book local "dignitaries" like Hacksaw and Sliwa for the show. Talk turns to broadcasting careers as Russell Wilson signs with CBS: Kap doubts the "corny Russ" reputation translates to TV. Dr. Klapper stops by to talk GLP-1s, Mitchell Robinson's dislocated knuckle and quick-pin surgery, plus Tommy Edmond's elongated ankle ligament repaired like a Tommy John procedure. Bergman hosts the Lindsey segment and talks Uber's Lost and Found Index (ankle monitors, live butterflies, Labubus) and the crew swaps animal-on-the-road stories. Dealer's Choice closes with Jared Verse showing zero respect taking number 8 from Dylan Gabriel in Cleveland while bringing relentless positivity to a losing team, capped by breaking news that Garrett agreed to a new five-year Rams deal. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Gretchen Burns Bergman, Executive Director of A New PATH, and Elon Burns, OD Prevention Specialist and Drug and Alcohol Counselor, discuss treating addiction as a public health issue, reducing the stigma of addiction and expanding access to naloxone/Narcan to save lives.  Bergman and Burns offer San Diego business and civic leaders insight into substance use disorders, workforce impact and effective community partnerships. Listen Where You Live!About Spotlight and Cloudcast Media  "Spotlight On The Community" is the longest running community podcast in the country, continuously hosted by Drew Schlosberg for 20 years.  "Spotlight" is part of Cloudcast Media's line-up of powerful local podcasts, telling the stories, highlighting the people, and celebrating the gravitational power of local.   For more information on Cloudcast and its shows and cities served, please visit www.cloudcastmedia.us. Cloudcast Media | the national leader in local podcasting.   About Mission Fed Credit Union  A community champion for over 60 years, Mission Fed Credit Union with over $6 billion in member assets, is the Sponsor of Spotlight On The Community, helping to curate connectivity, collaboration, and catalytic conversations.  For more information on the many services for San Diego residents, be sure to visit them at https://www.missionfed.com/

This week on The Shiver Show, Mary Labrie and Greg Flynn welcome you to step into one of the most psychologically unsettling stories ever brought to radio: “Gaslight” from Lux Radio Theatre, starring the legendary Ingrid Bergman and Charles Boyer.Long before the term became a pop psychology expression, Gaslight explored the terrifying power of manipulation, deception, and psychological control. Set in Victorian London, the story follows a young woman whose charming husband gradually convinces her that she is losing her mind. Strange noises echo through the house. Objects disappear. The gaslights flicker and dim. And every time she questions what's happening, she's calmly told it's all in her imagination.Bergman is superb as Paula, bringing vulnerability and emotional depth to every scene, while Boyer delivers a chilling performance full of charm, control, and quiet menace. Mary and Greg talk about how the title itself gave rise to the modern term “gaslighting.” Originally a stage play before becoming an acclaimed film and radio adaptation, Gaslight remains timeless because the only monster in this story is just an ordinary man.Thank you for listening!   If you like the show, please share us with your friends and family AND give us a review! If you have a suggestion for a show or a question, please drop it in the comments!Watch us on YouTube:https://www.youtube.com/@shivershowradioFollow The Shiver Show  https://www.facebook.com/theshivershowor check out our website at  https://www.timewarpstudios.com Other podcast platforms: https://linktr.ee/theshivershow

L'acteur et metteur en scène Charles Berlin signe la mise en scène du texte « C'est si simple l'amour » dans un dyptique consacré à l'auteur Lars Norén. Un huis-clos à l'humour mordant et aux dialogues acérés.  Deux couples d'amis se retrouvent pour fêter la première d'un spectacle mais au fur et à mesure que l'alcool délie les langues, ils vont se déchirer, exposer leurs failles, leur jalousie, leurs trahisons et révéler leurs vrais visages au terme d'une soirée explosive : « Lars Noren voulait écrire ce qui surgissait, sans se censurer », nous précise Charles Berling. Un salon bourgeois comme théâtre de l'explosion intime La pièce se déroule dans un immense salon bourgeois, décoré avec goût : une partie du public est placée sur scène, les spectateurs sont donc assis à deux pas du cœur de l'action « Je voulais matérialiser sur scène le fait qu'on a de moins en moins d'intimité ». Les canapés sont recouverts de draps blancs. « Au début, tout est beau, tout est emballé puis tout se délite ! »  Une tragicomédie selon Norén et Berling La pièce oscille entre humour noir et règlements de comptes sans pitié. Les dialogues sont très crus, les insultes foudroyantes : « quand la tragicomédie existe, quand les gens rient et sont effrayés, je suis  totalement heureux ». Malgré cela, la pièce ne bascule jamais dans le pathos. « Ce qu'il faut c'est qu'on rentre dans la pièce et qu'elle nous bouleverse, on a fait un grand travail de texte ».  « Lost and found » et « C'est si simple l'amour » font partie du cycle des 14 pièces écrites par Norèn entre 1989 et 1995.  Invité : Charles Berling, né en 1958 à Saint-Mandé, est un acteur, metteur en scène et réalisateur français. Issu d'une famille de diplomates, il passe son enfance entre l'Asie et l'Afrique, puis se forme au théâtre en France. Révélé au cinéma dans les années 1990, il se fait connaître du grand public avec des films comme « Nelly et Mr Arnaud », « Ridicule » ou « L'ennui ». Il mène en parallèle une importante carrière au théâtre, comme comédien et metteur en scène, et devient aussi directeur de lieux culturels (notamment à Toulon/Châteauvallon). Engagé, il défend une vision exigeante et populaire de la culture, entre cinéma d'auteur, théâtre et projets audiovisuels. Il dirige le Théâtre Chateauvallon Liberté Scène à Toulon.  Lars Göran Ingemar Norén est un poète, metteur en scène, dramaturge et auteur suédois, né le 9 avril 1944, à Stockholm en Suède, et mort le 26 janvier 2021. Il est considéré comme l'une des grandes voix du théâtre européen contemporain. Souvent rapproché de Strindberg ou de Bergman, il explorait dans ses pièces, les zones sombres de l'intime : familles en crise, secrets, maladies, solitude, violence sociale, racisme, dérive des marginaux.  C'est si simple l'amour : À voir au Théâtre de l'Atelier jusqu'au 1er juillet 2026. Programmation musicale : L'artiste Pépite avec le titre L'amertume. 

L'acteur et metteur en scène Charles Berlin signe la mise en scène du texte « C'est si simple l'amour » dans un dyptique consacré à l'auteur Lars Norén. Un huis-clos à l'humour mordant et aux dialogues acérés.  Deux couples d'amis se retrouvent pour fêter la première d'un spectacle mais au fur et à mesure que l'alcool délie les langues, ils vont se déchirer, exposer leurs failles, leur jalousie, leurs trahisons et révéler leurs vrais visages au terme d'une soirée explosive : « Lars Noren voulait écrire ce qui surgissait, sans se censurer », nous précise Charles Berling. Un salon bourgeois comme théâtre de l'explosion intime La pièce se déroule dans un immense salon bourgeois, décoré avec goût : une partie du public est placée sur scène, les spectateurs sont donc assis à deux pas du cœur de l'action « Je voulais matérialiser sur scène le fait qu'on a de moins en moins d'intimité ». Les canapés sont recouverts de draps blancs. « Au début, tout est beau, tout est emballé puis tout se délite ! »  Une tragicomédie selon Norén et Berling La pièce oscille entre humour noir et règlements de comptes sans pitié. Les dialogues sont très crus, les insultes foudroyantes : « quand la tragicomédie existe, quand les gens rient et sont effrayés, je suis  totalement heureux ». Malgré cela, la pièce ne bascule jamais dans le pathos. « Ce qu'il faut c'est qu'on rentre dans la pièce et qu'elle nous bouleverse, on a fait un grand travail de texte ».  « Lost and found » et « C'est si simple l'amour » font partie du cycle des 14 pièces écrites par Norèn entre 1989 et 1995.  Invité : Charles Berling, né en 1958 à Saint-Mandé, est un acteur, metteur en scène et réalisateur français. Issu d'une famille de diplomates, il passe son enfance entre l'Asie et l'Afrique, puis se forme au théâtre en France. Révélé au cinéma dans les années 1990, il se fait connaître du grand public avec des films comme « Nelly et Mr Arnaud », « Ridicule » ou « L'ennui ». Il mène en parallèle une importante carrière au théâtre, comme comédien et metteur en scène, et devient aussi directeur de lieux culturels (notamment à Toulon/Châteauvallon). Engagé, il défend une vision exigeante et populaire de la culture, entre cinéma d'auteur, théâtre et projets audiovisuels. Il dirige le Théâtre Chateauvallon Liberté Scène à Toulon.  Lars Göran Ingemar Norén est un poète, metteur en scène, dramaturge et auteur suédois, né le 9 avril 1944, à Stockholm en Suède, et mort le 26 janvier 2021. Il est considéré comme l'une des grandes voix du théâtre européen contemporain. Souvent rapproché de Strindberg ou de Bergman, il explorait dans ses pièces, les zones sombres de l'intime : familles en crise, secrets, maladies, solitude, violence sociale, racisme, dérive des marginaux.  C'est si simple l'amour : À voir au Théâtre de l'Atelier jusqu'au 1er juillet 2026. Programmation musicale : L'artiste Pépite avec le titre L'amertume. 

durée : 00:18:04 - Les émissions culturelles de France Culture - par : Marie Labory - Le metteur en scène Markus Öhrn s'attaque à l'œuvre de son compatriote suédois Ingmar Bergman en adaptant pour le théâtre "Scenes of a marriage" portée par deux comédiens masqués. - réalisation : Laurence Malonda, Boris Pineau, Aïssatou N'Doye, Jules Barbier, Zohra Vignais, Lise Ripoche, Mathi Adjinsoff - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O, Victor Inisan docteur en études théâtrales, dramaturge et critique Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 01:06:15 - Le célèbre parolier, musicien, romancier, acteur et dramaturge français prend les rênes de notre programmation et partage ses coups de cœur. - réalisation : Gaëlle Renard, Boris Bergman, Denis Soula - invités : Boris Bergman Parolier, romancier, dramaturge Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Municipalities, nonprofit, residents challenge review As anticipated by votes earlier this month by the Cold Spring and Philipstown boards, the municipalities on Wednesday (May 20) filed a state lawsuit challenging the conclusions of a mandated environmental review of the proposed 7.5-mile linear park that would connect Beacon to Cold Spring. At the same time, a nonprofit group, Protect the Highlands, filed its own lawsuit. The legal actions name Hudson Highlands Fjord Trail Inc., a subsidiary of Scenic Hudson, and the state Office of Parks, Recreation and Historic Preservation. Both allege that a recently completed state environmental review fails to adequately assess the project's impact on the village and town. The lawsuits had to be filed before May 20, or 120 days after the end of the environmental review process, to meet a state deadline. The legal actions are Article 78 proceedings, which enable municipalities and others to challenge the actions or inactions of local and state agencies. Protect the Highlands filed its challenge in Albany County, along with four Cold Spring residents — Tom Impellittiere, Stephanie Impellittiere, Stephanie Skiptunis and Rosanne Powell — whom the filing says "will suffer direct environmental, aesthetic and community impacts distinct from those experienced by the public at large." The village and town filed their lawsuit in Putnam County. The municipalities hope to have Putnam County join them, but the Legislature did not vote on the request before the filing deadline. At the Wednesday meeting of the Village Board, Mayor Kathleen Foley said that the lawsuit "does not stop the project, as some have erroneously asserted," but that "we would be delinquent in our duties if we did not challenge the findings." She said that, earlier in the week, the village received an email signed by residents who support the Fjord Trail, requesting a referendum on the project. Foley said a vote "is not a possibility under state law." She added that she could say "with certainty that even if every resident in this village stated their unconditional support for the Fjord Trail project, this board would still be asking fiscal, environmental and quality-of-life questions." The lawsuit also names Putnam County, and Cold Spring resident Laura Bergman, which Foley said was done to give both the opportunity to join as petitioners or respondents. Bergman owns property at the entrance to Dockside Park. Both lawsuits focus on the southern section of the trail, from Cold Spring to Breakneck Ridge. In February, HHFT said it would delay construction on the southern end by at least two years to collect data on a stretch of the Hudson River where an elevated boardwalk is planned. A pedestrian bridge at Breakneck, which underwent a separate environmental review in 2022, is under construction, along with a parking lot on Route 9D across from the former Dutchess Manor, which will be the HHFT headquarters. Protect the Highlands alleges that the state's "findings statement," which cleared the way for HHFT to move forward, was "arbitrary, capricious and irrational on several fronts" and should be annulled. The municipal suit asks that the findings statement be nullified for the southern section, and notes that HHFT must get land-use and Zoning Board approvals from Cold Spring and Philipstown for sections of the trail on private property or within the state park. (The environmental review concluded that HHFT does not need local approval for parts of the trail built on state land.) In addition, the suit says that access to Dockside Park, which is owned by the state and maintained by the village, would only be available through an easement on private land. It asks the court to rule that the easement does not provide the access required to reach the trail. Cold Spring and Philipstown argue that concerns regarding traffic and emergency services "were marginalized, if not completely ignored," and that several findings were "arbitrary a...

Time for Sports Graffiti! Mason and Ireland dive into the story of a golf caddy being fired. Was Ohtani almost traded to the Rays from the Angels? Bergman drops into the studio! Who did the Dodgers almost trade away? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Rep. Jack Bergman (R-MI), co-chair of the Congressional Postal Caucus,  joins Bob to discuss the activities of the bipartisan panel and the importance of a universal, accessible, and affordable national postal system. The congressman and Bob also discuss postal accountability. Finally, in recognition of Memorial Day, Rep. Bergman, a retired Marine Corps Lieutenant General, reflects on how mail connects members of the armed forces deployed overseas with the family and friends back home.  

durée : 00:30:08 - Les Nuits de France Culture - par : Albane Penaranda - Renoir ou Bergman sans Palme d'or ? Alors que valent les palmarès de Cannes ? Dans cette émission de 2002, Antoine Guillot, entouré de Nelly Kaplan, Jean Douchet et Antoine de Baecque, interroge l'histoire des prix du Festival, entre choix consensuels et chefs-d'œuvre incontournables. - réalisation : Rafik Zénine, Hassane M'Béchour, INA - invités : Nelly Kaplan Écrivaine et réalisatrice Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

In a special episode from Cannes 2026, Christina interviews (her husband:), screenwriter Peter Birro, and director Gustaf Skarsgård about their upcoming film. They are at the festival to introduce The Cannibal, a psychological horror film about a screenwriter who goes to the island of Fårö to write a movie about Bergman, but soon encounters a demonic presence. Production starts in 2026. Audio & Video Video by Anton Isiukov https://www.antonisiukov.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Time for Sports Graffiti! Mason and Ireland hit the phones for bonus Graffiti! The crew pivots back to the Dodgers with Bergman for another ‘Boys in Blue Report!' Ireland shares a story from today's PGA Championship. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Peter Birro och Gustaf Skarsgård ska göra film tillsammans. Filmen ska heta Kannibalen på Fårö och innehålla mycket - hjärta, skräck och skratt. Lyssna på alla avsnitt i Sveriges Radios app. ”Gustaf Skarsgård regidebuterar med Kannibalen på Fårö, en totalt gränsöverskridande historia om filmskapandets möjligheter och irrvägar med manus av Peter Birro.” Så beskriver filmbolaget filmplanerna som presenterades på Film i Västs pressträff i Cannes.Björn Jansson har träffat de två för att höra mer om planerna, där Ingmar Bergman figurerar både som geni och demon. Och vi får också reda på vad som skrämde livet ur de två när de var åtta-åringar.

What happens when your carefully planned, low-intervention birth transforms into something entirely unexpected? In this replay episode, Dr. Rebecca Dekker revisits her conversation with Leah Bergman, a graduate of the Evidence Based Birth® Childbirth Class, and her birth story of navigating a surprise diagnosis of fetal growth restriction (sometimes called intrauterine growth restriction or IUGR) in late pregnancy. Together, they unpack the emotional rollercoaster of changing birth plans, wrestling with uncertainty, and making tough decisions around induction while still finding space for empowerment, advocacy, and joy. Leah opens up about leaning on evidence-based education, support from her husband and doula, and a compassionate midwifery team as she faced a challenging induction process complete with surprises, setbacks, and two trips to the hospital. You'll also hear practical strategies for advocating during labor, the realities of taking a break from an induction then "starting over", and how to build a positive birth experience even when things go off script. Content Note: Discussion of the risk of stillbirth associated with fetal growth restriction. (03:44) Discovering Evidence Based Birth® (09:15) Deciding to induce labor(10:43) Placenta health and birth timing(14:50 Discussing timing of delivery(17:41) Labor induction experience(23:29 Beginning stages of labor induction(25:55) Advocating for rest during labor(28:48) Unexpectedly quick delivery experience(31:51) Managing baby's low birth weight   For the full list of resources from this epiosde, click here. For more information about Evidence Based Birth® and a crash course on evidence based care, visit www.ebbirth.com. Follow us on Instagram and YouTube! Ready to learn more? Grab an EBB Podcast Listening Guide or read Dr. Dekker's book, "Babies Are Not Pizzas: They're Born, Not Delivered!" If you want to get involved at EBB, join our Professional membership (scholarship options available) and get on the wait list for our EBB Instructor program. Find an EBB Instructor here, and click here to learn more about the EBB Childbirth Class.

The guys start the show off reacting to the Lakers' elimination loss. Morales leaned into the chaos and storylines ahead. Sedano and Kap gave the Lakers credit for fighting to the end against a clearly better OKC team and Bergman is sad. Sure, the Lakers got swept - but they were sooo close! Did you think they had it? Is there a world in which they could/should have won? JJ Redick was very reflective in his postgame press conference, and both Sedano and Kap have thoughts on what he said. Sedano made the case that JJ Redick is the best Lakers coach of the last three because he actually coaches instead of managing egos. Dodgers talk! Berg's 3 things: Roki Sasaki's encouraging start, Mookie Betts back in the No. 2 spot, Shohei is a MESS at the plate! Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode Matt and Jon discuss the surprise Bear episode "Gary", then The Boys and Hacks, while Jon finished Maul: Shadow Lord and Daredevil: Born Again while Matt watched Bergman's Shame and crossed the halfway point on Six Feet Under! Threads: https://www.threads.net/@jonwahizzle Facebook: https://www.facebook.com/groups/damnthattelevision/ Instagram: https://www.instagram.com/damntvpod Bluesky: https://bsky.app/profile/mattlovestv.bsky.social https://bsky.app/profile/jonwahizzle.bsky.social Letterboxd: https://letterboxd.com/mattlovestv/ https://letterboxd.com/jonwahizzle/ Jon on AIPT: https://aiptcomics.com/author/jonathanw/ Matt's show The Drop: A Pop Culture Mix Tape: wscafm.org Sundays 6-8 PM: https://www.facebook.com/groups/thedropwsca/

Time for Sports Graffiti! Mason and Ireland get more calls from Laker fans ahead of game two tonight! The guys are joined by special guest, President and CEO of the Dodgers, Stan Kasten! The guys discuss and celebrate the life of Ted Turner with Kasten! Bergman drops into the studio for another ‘Boys in Blue' report! Learn more about your ad choices. Visit podcastchoices.com/adchoices

OA1258 - The Social Media Victims Law Center just made history in a Los Angeles courtroom by holding Meta and Google accountable for mental health harms which they successfully argued to a jury knowingly caused harm to children. In a novel legal theory, these plaintiffs argued that they were harmed not through a lack of content moderation or other editorial choices which might otherwise be protected by Section 230 of the Communications Decency Act, but by the fundamental design of platforms like Facebook, Instagram, TikTok, and Youtube. SMVLC founder Matthew Bergman joins to share how his decades of litigating on behalf of people harmed by asbestos brought him to this groundbreaking lawsuit and what it might mean for the thousands of other actions the SMVLC has brought around the US, as well as the upcoming claims which will be litigated by state AGs later this year. Where do the immunities guaranteed by Section 230 of the Communications Decency Act end and the harmful and potentially addicting features which social media platforms have knowingly baked into the design of their platforms begin? Is “social media addiction” a demonstrable mental health issue or just a way to pathologize a bad habit? And could these well-meaning suits pose any threats to our privacy and civil liberties in the name of protecting children? We take on these and many more of the questions raised by some of the most fascinating and controversial civil litigation of the 21st century so far. Attorney Matthew Bergman's bio from Lewis & Clark Law's website Social Media Victims Law Center website Addiction By Design, Natasha Dow Shull, Princeton University Press (2014) Lemmon v. Snap, Inc., 995 F.3d 1085 (9th Cir. 2021) Check out the OA Linktree for all the places to go and things to do!

Time for Sports Graffiti! Mason and Andy Kamenetzky continue with the phones to hear from more Lakers fans! The guys are joined by a special guest, Max Kellerman! What does Max think about the Lakers and Rockets series? Bergman joins the show for another ‘Boys in Blue' Report! Does Freeman need a little rest? Learn more about your ad choices. Visit podcastchoices.com/adchoices

durée : 00:46:13 - Le masque et la plume - par : Rebecca Manzoni - "Le Cid" par la troupe de la Comédie française, Pauline Bureau avec "Entre parenthèses" et "Top Hat" claque des talons au Châtelet. Le Masque ausculte aussi Mélody Mourey, Bergman et Océan. Critique, éloge, volées de bois vert : nos critiques tranchent. - réalisation : Stéphane Le Guennec, Ilinca Negulesco - invités : Fabienne Pascaud Journaliste chez Télérama, Pierre Lesquelen Critique à I/O Gazette et Détectives sauvages, dramaturge et enseignant-chercheur, Sandrine Blanchard Journaliste au Monde, Laurent Valière Producteur Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Time for Sports Graffiti! Mason and Ireland are joined by Ramona Shelburne! Momo was in San Antonio last night where Wemby got a concussion. The Dodgers are in SF to take on the Giants! Dave Roberts and John Schneider sat down with Jeff Passan to discuss the 2025 World Series! Bergman joins the guys in the studio for another ‘Boys in Blue Report!' Learn more about your ad choices. Visit podcastchoices.com/adchoices

Religious Month continues with one of the most iconic and philosophical films ever made — The Seventh Seal by Ingmar Bergman.Set during the Black Death, the film follows a knight who returns home only to encounter Death himself — and challenges him to a game of chess in a desperate search for meaning. Through striking imagery and quiet conversations, Bergman explores faith, doubt, mortality, and the silence of God.We dive into the film's unforgettable symbolism, its lasting impact on cinema, and why its questions about life and belief still resonate today. From its haunting visuals to its existential core, The Seventh Seal is as thought-provoking as it is timeless.Bleak, beautiful, and deeply human — this is cinema wrestling with the biggest questions of all.#WatchTowerFilmPodcast #ReligiousMonth #SeventhSeal #IngmarBergman #ClassicCinema #ExistentialFilm #FaithAndFilm #FilmPodcast #CinephileTalk

Cam Zurhaar headlines the week with a monster performance in a new half-back role, showing just how valuable role shifts can be in keeper formats. It's not often you see a bull that far from his paddock and rack it up like that, and it's already sparked plenty of waiver wire movement.Elijah Tsatas continues his rise since returning to Essendon's side, starting to put it all together with his midfield work. The signs are strong that this is no longer just potential - this could be the breakout stretch.Miles Bergman looks like he might finally be back. With Port controlling the game and allowing their defenders to accumulate, we saw glimpses of the scoring profile we know he's capable of. The big question now: is this the turning point or just a one-off?We also dive into the evolving 2G4P landscape, with more players ticking the boxes and others falling just short. Role changes, CBAs, and team trends are becoming more reliable indicators, and identifying these early is key to staying ahead in keeper leagues.Across the competition, there's a growing list of up-and-coming players putting their hand up — whether it's through increased midfield time, new roles, or simply taking their opportunity. Knowing which of these are real and which are noise is what separates the good teams from the great ones.And finally… is Andrew Brayshaw no longer too good for the podcast? Find out in this episode.If you're playing draft and keeper leagues, this episode is packed with the insights you need to stay ahead of the curve.Become a Keeper League Podcast member:https://keeperleaguepod.com.au/keeper-league-membership/Join our Discord:https://discord.gg/APjqvT22zePlay FootyNumbers:https://footynumbers.comPlay FootyHeads:https://footyheads.com

For the full episode, subscribe here to Inside Call me Back. ____ Subscribe to Ark News Daily ____ This is a sneak peek from the members-only edition of Inside Call Me Back, the final installment of our four-part series with Ronen Bergman. After the U.S. exits the JCPOA, Israel and the U.S. launch a campaign of sanctions, sabotage, and targeted assassinations, what Bergman calls “death by a thousand cuts.” In this preview, Bergman details the AI-assisted assassination of Iran's top nuclear scientist and why, despite the scale and sophistication of the operation, it was not enough to stop Iran's nuclear program. More Ark Media: Want to join Ark Media? Check out our careers page for new openings. Explore Israel Votes Listen to For Heaven's Sake Listen to What's Your Number? Watch Call me Back on YouTube Newsletters | Ark Media | Amit Segal | Nadav Eyal Instagram | Ark Media | Dan X | Dan Dan Senor & Saul Singer's book, The Genius of Israel Get in touch Credits: Ilan Benatar, Adaam James Levin-Areddy, Brittany Cohen, Ava Weiner, Martin Huergo, Mariangeles Burgos, and Yuval Semo

Mason and Ireland tip off the show today with news of Luka Doncic and Cade Cunningham winning their appeal so they can be eligible for season awards. Take a listen to Steve Kerr talking about Steph Curry. How would you describe the Clippers season? The guys dive into a NFL Draft story, as the draft is just one week away! Bergman joins the guys in the studio for another, ‘Boys in Blue Report!' Ohtani just pitched last night and instead of both ways, will that be more common this season? Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Påskeferien prøvede at nedlægge os med en arrig dobbelt-combo: Casper har svedt tran med 40 i feber midt i en vaskeægte 'Amadeus'-katastrofe i Grand Teatret, mens Jannik har kæmpet mod en decideret middelalderlig halsbyld. Men stormen er redet af, og nu er vi endelig klar til at snakke lidt om film igen, og endda af den gode slags. Vi lægger benhårdt ud med den britiske Tourettes-dramedy 'I Swear'. Nogle kalder den noget af det sjoveste, de længe har set, men vi undersøger, om man ikke misser pointen fuldstændig, hvis man udelukkende griner. Vi ser nærmere på ubehagelig komik, Robert Aramayos fantastiske præstation og en både sjov og rørende tragikomisk fortælling om en mand, der har decideret svært ved at etablere sig som et helt almindeligt menneske. Spørgsmålet er, hvorfor har englænderne altid været sindssygt gode til at få ekstremt høj kvalitet ud af ensporet følelsesporno.  Derfra suser vi direkte ind i det lidt unikke børnesyn i den Oscar-nominerede animationsfilm 'Lille Amélie'. Her lugter det langt mere af Miyazaki end af Pixar, når filmen ret modigt tager livets allerstørste spørgsmål under kærlig behandling. Alt sammen set fra et barns særlige, og indledningsvist fuldstændig ubevægelige, perspektiv. Episodens hovedret er Joachim Triers længe ventede norske sensation, 'Affektionsværdi'. Vi dykker ned i det komplekse, Bergman-inspirerede familiedrama spækket med metalag og en solid Stellan Skarsgård i rollen som martret filminstruktør. Men formår den overhovedet at ramme os lige så rent i hjertekulen som Triers andre Oslo-fortællinger? Til sidst tænder vi for Seriemorteren. Ikke for at dele stjerner ud, for det har vi ikke set nok til, men for at dele lidt umiddelbare 'feels' og tanker fra sofaen. Vi kaster et undrende blik på den vilde klatretøsen-farvegraduering og nuller-nostalgi i Netflix' storstilede Jo Nesbø-satsning 'Harry Hole', tjekker ind hos Trine Dyrholm i den dejligt underlige islandsk-danske thriller 'Den danske kvinde', og runder lynhurtigt Handmaid's Tale-spinoff'en 'The Testaments'. Længere er den ikke. Det var, hvad vi kom for. Vi ses i biffen, og vi høres ved på Hjørnet! Med venlig hilsen,Casper & Jannik

A classic Bergman film. Well, a classic Martin Bergman film. About Temecula.  Where your favorite podcast hosts first met.  Anyway… two neurotic New Yorkers - with ulterior motives - take on a couple of quick gigs in the wine country of (southern) California. Perhaps romance is in the air for this strangely legit cast? *Come support the podcast and get yourself or someone you love a random gift at our merch store.  T-shirts, hoodies, mugs, stickers, and more! If you'd like to watch ahead for next week's film, we will be discussing and reviewing Josef von Sternberg's Underworld (1927).

Time for Sports Graffiti! Ireland and Ramona Shelburne are joined by Bergman for another ‘Boys in Blue Report!' It's Masters Week! The crew looked at a story out ahead of the WNBA draft. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode Matt and Jon discuss The Pitt, the penultimate Shrinking, the literally gut wrenching Invincible and the Fall and Rise of Reggie Dinkins while Jon saw Daredevil: Born Again, DTF St. Louis and They Will Kill You as well as read the beginning of Stephanie Phillips' Daredevil run while Matt began the new season of For All Mankind, finished Paradise, and continues Bergman with The Magician, The Virgin Spring and The Devil's Eye. Threads: https://www.threads.net/@jonwahizzle Facebook: https://www.facebook.com/groups/damnthattelevision/ Instagram: https://www.instagram.com/damntvpod Bluesky: https://bsky.app/profile/mattlovestv.bsky.social https://bsky.app/profile/jonwahizzle.bsky.social Letterboxd: https://letterboxd.com/mattlovestv/ https://letterboxd.com/jonwahizzle/ Jon on AIPT: https://aiptcomics.com/author/jonathanw/ Matt's show The Drop: A Pop Culture Mix Tape: wscafm.org Sundays 6-8 PM: https://www.facebook.com/groups/thedropwsca/

Mason and Ireland tip off the show with the Lakers vs Thunder tonight in OKC! Could tonight's game be a playoff preview? Luka has been named Western Conference Player of the Month for March! Are the guys interested in space travel? The Raiders have signed QB Kirk Cousins, and Ireland absolutely loves this move. Bergman drops into the studio for another ‘Boys in Blue Report!' Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Time for Sports Graffiti! Mason and Ireland are joined by Bergman for another ‘Boys in Blue' Report! The crew pivot to the Lakers and if their current defense will hold up in the playoffs? How impressive was the Lakers recent winning streak? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Replay!On today's episode of Architectette we share a conversation with Jill Bergman, FAIA, FACHA. Jill is a Senior Health Strategist at HDR, based in San Francisco, California. She has focused on healthcare facility design for her entire career, mostly working on large projects and medical planning. We talk about: - The power of focusing her career on one specific project type and how her after-work involvement helped her deepen her knowledge of healthcare architecture, build a strong community, and expand her impact.- Her recent elevation to FAIA and why she was advised to consider applying as a milestone, rather than a lifetime achievement (fun fact: it's both!).- We next talk about Jill's early career experience as a mentee and how she draws from that experience as she heads the AIA Academy of Architecture for Health, Colleague 2 Colleague Mentorship Program.- We talk a bit about applying the “yes, and...” principles of improv to architecture and Jill shares a few specific lessons from her incredible standing-room only 2023 Women's Leadership Summit Session.- We end by discussing how data analytics and benchmarking as well as in-person shadowing experiences in the hospital have influenced her work as an architect.>>>Connect with Architectette:- Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ www.architectette.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Learn more)- Instagram:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ @architectette⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (See more)- Newsletter:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ www.architectette.com/newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Behind the Scenes Content)- LinkedIn:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ The Architectette Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Page and/or⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Caitlin Brady⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠>>>Support Architectette:- Leave us a rating and review!>>>Music by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ AlexGrohl⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ from ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Pixabay⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

I've interviewed many law firm leaders on this podcast, usually from one of two extremes: brand-new boutiques or long-established Biglaw institutions. But the most interesting moment in a firm's history may be the middle—when the early bets have paid off, but the long-term trajectory is still unfolding.That's where Glenn Agre Bergman & Fuentes is today. Founded in February 2021, in the depths of the pandemic, the firm is now one of the nation's leading boutiques—and recently marked its fifth anniversary with a celebration at The Pool, a fabulous venue inside the landmark Seagram Building.I was there at the invitation of my longtime friend Jed Bergman—a former Wachtell Lipton colleague and co-founder of Glenn Agre, where he recently became the chair of litigation. After catching up at the party, I invited Jed to join me on the podcast to talk about what it's like to be five years into building a firm.Five years is a revealing moment: long enough to have learned lessons, but early enough that the future remains wide open. Jed and I discussed why he and his partners launched Glenn Agre, what he knows now that he didn't then, where the firm is headed—and why he thinks AI could give boutiques a competitive edge over Biglaw.Congratulations to Jed and his partners on the milestone—and best of luck in the years ahead.Show Notes:* Jed I. Bergman bio, Glenn Agre Bergman & Fuentes LLP* Jed Bergman profile, Legal 500* Jed I. Bergman Appointed Chair of Litigation Department at Glenn Agre Bergman & Fuentes LLP, PR NewswirePrefer reading to listening? For paid subscribers, a transcript of the entire episode appears below.Sponsored by:NexFirm helps Biglaw attorneys become founding partners. To learn more about how NexFirm can help you launch your firm, call 212-292-1000 or email careerdevelopment@nexfirm.com. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit davidlat.substack.com/subscribe

Mickey Bergman, who negotiates the release of political prisoners, returns to explain how freeing hostages from the world's most hostile regimes runs entirely on emotional intelligence, not geopolitical leverage. He walks through two cases — using Bill Richardson's death to unlock a Venezuelan prisoner release, and a single carefully orchestrated meeting with Myanmar's military junta leader. Bergman also discusses the Gilad Shalit exchange that put Yahya Sinwar back in circulation. Plus, Mike updates the March Madness bracket with injury news: Ali Larijani is out for the tournament. And in the Spiel, why Burger King's Baba O'Riley rebrand is less a comeback than a confession. Produced by Corey Wara Video and Social Media by Geoff Craig Do you have questions or comments, or just want to say hello? Email us at ⁠⁠⁠⁠thegist@mikepesca.com For full Pesca content and updates, check out our website at https://www.mikepesca.com/⁠ For ad-free content or to become a Pesca Plus subscriber, check out ⁠⁠⁠⁠https://subscribe.mikepesca.com/ For Mike's daily takes on Substack, subscribe to The Gist List https://mikepesca.substack.com/ Follow us on Social Media:⁠⁠⁠⁠ YouTube https://www.youtube.com/channel/UC4_bh0wHgk2YfpKf4rg40_g⁠⁠⁠⁠ Instagram https://www.instagram.com/pescagist/ X https://x.com/pescami TikTok https://www.tiktok.com/@pescagist To advertise on the show, contact ⁠⁠⁠⁠ad-sales@libsyn.com⁠⁠⁠⁠ or visit ⁠⁠⁠⁠https://advertising.libsyn.com/TheGist

Today on The Gist, Global Reach CEO Mickey Bergman discusses the high-stakes world of international hostage negotiation. He details the emotional intelligence required to deal with foreign officials and clarifies the behind-the-scenes realities of securing the release of Americans like Paul Whelan, Trevor Reed, and Brittney Griner. Plus, Mike opens the show by analyzing the Republican-backed SAVE Act. He argues the proof-of-citizenship voting bill is purely a messaging tactic with no chance of passing the Senate, and points out that many of the voters most likely to lack ready access to a birth certificate actually favor Donald Trump.  Produced by Corey Wara Video and Social Media by Geoff Craig Do you have questions or comments, or just want to say hello? Email us at ⁠⁠⁠⁠thegist@mikepesca.com For full Pesca content and updates, check out our website at https://www.mikepesca.com/⁠ For ad-free content or to become a Pesca Plus subscriber, check out ⁠⁠⁠⁠https://subscribe.mikepesca.com/ For Mike's daily takes on Substack, subscribe to The Gist List https://mikepesca.substack.com/ Follow us on Social Media:⁠⁠⁠⁠ YouTube https://www.youtube.com/channel/UC4_bh0wHgk2YfpKf4rg40_g⁠⁠⁠⁠ Instagram https://www.instagram.com/pescagist/ X https://x.com/pescami TikTok https://www.tiktok.com/@pescagist To advertise on the show, contact ⁠⁠⁠⁠ad-sales@libsyn.com⁠⁠⁠⁠ or visit ⁠⁠⁠⁠https://advertising.libsyn.com/TheGist

Time for Sports Graffiti! Mason and Ireland are joined by Bergman for another “Boys in Blue” report! Team USA takes on team Canada tonight in the first knockout round of the World Baseball Classic! Why did MLB review a play in game 7 of the World Series? Should students be banned from using E-Bikes? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. John Bergman, a renowned chiropractor with a focus on neurology, sheds light on the deficiencies of the current "sick care system," advocating for a transformative outlook on healthcare that honors the body's natural capacity for healing. The episode kicks off with a captivating discussion on chronic illness statistics, forcing listeners to rethink traditional medical paradigms. Dr. Bergman's candid perspectives on alternative medicine, backed by years of practice and academic enrichment, foster a dynamic narrative throughout the episode.Delving into preventative health measures and the philosophy of mind-body synergy, Dr. Bergman underscores his passion for overturning conventional medical approaches. Keywords like "self-healing," "regeneration," and "alternative healthcare" dominate the conversation as he elaborates on the three stressor components—physical, chemical, and emotional—and their impact on health. The discussion takes intriguing turns into the realms of energy frequency, the power of thought, and quantum physics, offering listeners a deep dive into innovative concepts. This episode serves as a profound call to action for individuals seeking to empower themselves through holistic wellness.Key Takeaways:Revolutionizing Health Perception: Dr. Bergman challenges the traditional healthcare system, emphasizing a need to view the body as inherently self-healing and self-regulating.Root Cause of Disease: The conversation reveals insights into how diseases are adaptations to stressors—physical, chemical, and emotional—rather than standalone entities.Effective Health Strategies: Regular joint movement, natural diet conforming to ancestral habits, and stress management through prayer and meditation are advocated as core health strategies.Quantum and Energy Paradigms: Dr. Bergman discusses the scientific basis for energy's role in health, including the potential for thought to influence physiological outcomes.Cultural and Global Health Insights: With clinics worldwide, Dr. Bergman shares comparative insights on health perceptions and practices across different cultures.Notable Quotes:"Disease doesn't exist, it's really the body adapting.""If you look at America, we are the sickest industrialized nation in the world.""When you learn to tap into energy, that's when you can bypass gravity.""The body can regenerate itself. Oh, that's the message, baby.""Einstein said you can look at everything as if there's no magic or if everything's magic."Connect with Dr. John Bergman:WebsiteYoutubeInstagramConnect with Rudy Mawer:LinkedInInstagramFacebookTwitter

We start the show off with some super cross talk with Mason, & Ireland. The guys are both in studio along with Greg Bergman who joins us every Wednesday each week. Bergman is still sad after the Max Crosby trade to the Ravens got rescinded. The Lakers defeated the Minnesota Timberwolves last night in a convincing fashion after defeating the New York Knicks without LeBron James in both games. D'Marco tells us a story on MC Hammer and how he became friends with him. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mason is joined by Ireland live from Denver! The Lakers take on the Nuggets tonight and have a tough stretch in the next few games. The crew circle back to the Atlanta Hawks promo night for ‘Magic City!' Bergman drops into the studio for a ‘Boys in Blue” report! Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Time for Sports Graffiti! Mason, Ireland, and Pepe Mantilla are joined by Bergman for a “Boys in Blue” report! How do the Dodgers look so far in Spring Training? What was the gift Todd Monken got for his birthday? Which team got the worst report card in the NFL? How did the Rams score on the NFL team report cards? Should the Rams make a move for Maxx Crosby? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Time for Sports Graffiti! Mason and Andy Kamenetzky circle back to the most underrated movies. Bergman drops into the studio for a Boys in Blue Report! Who will be the Dodgers starting second baseman this season? The crew dive a little into the Rams and what they will do this offseason? Who does Mason feel bad for? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Melissa Lavasani & Jay Kopelman join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads Psychedelic Medicine Coalition, a DC-based advocacy organization focused on educating federal officials and advancing legislation around psychedelic medicine. Kopelman is CEO of Mission Within Foundation, which provides scholarships for veterans and first responders seeking psychedelic-assisted therapy retreats, often outside the United States. The conversation centers on veterans, the VA, and why that system may be the first realistic federal pathway for psychedelic care. Early Themes Lavasani describes PMC's work on Capitol Hill, including hosting events that bring lawmakers, staffers, and advocates into the same room. Her focus is steady engagement. In DC, progress often happens through repeated conversations, not headlines. Kopelman shares his background as a Marine and how his own psychedelic-assisted therapy experience led him to Mission Within. The foundation has funded more than 250 scholarships for veterans and first responders seeking treatment for PTSD, mild traumatic brain injury, depression, and addiction. They connect this work to pending veteran-focused legislation and explain why the VA matters. As a closed health system, the VA can pilot programs, gather data, and refine protocols without the pressures of private healthcare markets. Core Insights A recent Capitol Hill gathering, For Veteran Society, brought together members of Congress and leaders from the psychedelic caucus. Lavasani describes candid feedback from lawmakers. The message was clear: coordinate messaging, avoid fragmentation, and move while bipartisan interest remains. Veteran healthcare is not framed as the final goal. It is a starting point. If psychedelic therapies can demonstrate safety and effectiveness within the VA, broader adoption becomes more plausible. Kopelman raises operational realities that must be addressed: Standardized safety protocols across providers Integration support, not medication alone Clear training pathways for clinicians Real-world data beyond tightly screened clinical trials They also address recent negative headlines involving ibogaine treatment abroad. Kopelman emphasizes the need for shared learning across providers, especially when adverse events occur. Lavasani argues that inconsistency within the ecosystem can slow federal confidence. Later Discussion and Takeaways The discussion widens to federal momentum around addiction and mental health. Lavasani notes that new funding initiatives signal growing openness to innovative treatment models, even if psychedelics are not named explicitly in every announcement. Both guests stress that policy moves slowly by design. Meetings, follow-ups, and relationship building often matter more than public statements. For clinicians, researchers, operators, and advocates, the takeaways are direct: Veterans are likely the first federal pathway Public education remains essential Safety standards must be shared and transparent Integration and workforce development need attention now If psychedelic medicine enters federal systems, infrastructure will determine success. Frequently Asked Questions What do Melissa Lavasani & Jay Kopelman say about VA psychedelic policy? They argue that veteran-focused legislation offers a realistic first federal pathway for psychedelic-assisted care. Is ibogaine currently available through the VA? No. They discuss ibogaine in the context of private retreats and future possibilities, not an existing VA program. Why do Melissa Lavasani & Jay Kopelman emphasize coordination? Lawmakers respond more positively when advocates present aligned messaging and clear priorities. What safety issues are discussed by Melissa Lavasani & Jay Kopelman? They highlight the need for standardized screening, monitoring, integration support, and transparent review of adverse events. Closing Melissa Lavasani & Jay Kopelman provide a grounded look at how psychedelic policy develops inside federal systems. Their message is practical: veterans may be the first lane, but long-term success depends on coordination, safety standards, and sustained engagement. Closing This episode captures a real-time view of how federal policy could shape the next phase of the psychedelic resurgence, especially through veteran-facing legislation and VA infrastructure. Melissa Lavasani & Jay Kopelman argue that coordination, public education, and shared safety standards will shape whether access expands with credibility and care. Transcript Joe Moore: [00:00:00] Hello everybody. Welcome back to Psychedelics Today. Today we have two guests, um, got Melissa Sani from Psychedelic Medicine Coalition. We got Jake Pelman from Mission Within Foundation. We're gonna talk about I bga I became policy on a recent, uh, set of meetings in Washington, DC and, uh, all sorts of other things I'm sure. Joe Moore: But thank you both for joining me. Melissa Lavasani: Thanks for having us. Jay Kopelman: Yeah, it's a pleasure. Thanks. Joe Moore: Yeah. Um, Melissa, I wanna have you, uh, jump in. First. Can you tell us a little bit about, uh, your work and what you do at PMC? Melissa Lavasani: Yeah, so Psychedelic Medicine Coalition is, um, the only DC based Washington DC based advocacy organization dedicated to the advancing the issue of psychedelics, um, and making sure the federal government has the education they need, um, and understands the issue inside out so that they can generate good policy around, around psychedelic medicines. Melissa Lavasani: [00:01:00] Uh, we. Host Hill events. We host other convenings. Our big event every year is the Federal Summit on psychedelic medicine. Um, that's going to be May 14th this year. Um, where we talk about kinda the pressing issues that need to be talked about, uh, with government officials in the room, um, so that we can incrementally move this forward. Melissa Lavasani: Um, our presence here in Washington DC is, is really critical for this issue's success because, um, when we're talking about psychedelic medicines, um, from the federal government pers perspective, you know, they are, they are the ones that are going to initiate the policies that create a healthcare system that can properly facilitate these medicines and make sure, um, patient safety is a priority. Melissa Lavasani: And there's guardrails on this. And, um, you know, there, it's, it's really important that we have. A home base for this issue in Washington DC just [00:02:00] because, uh, this is very complicated as a lot of your viewers probably understand, and, you know, this can get lost in the mix of all the other issues that, um, lawmakers in DC are focused on right now. Melissa Lavasani: And we need to keep that consistent presence here so that this continues to be a priority for members of Congress. Joe Moore: Mm. I love this. And Jay, can you tell us a bit about yourself and mission within Foundation? Jay Kopelman: Yeah, sure. Joe, thanks. Uh, I, I am the CEO of Mission within Foundation. Prior to this, most of my adult life was spent in the military as a Marine. Jay Kopelman: And I came to this. Role after having, uh, a psychedelic assisted therapy experience myself at the mission within down in Mexico, which is where pretty much we all go. Um, we are here to help [00:03:00] provide, uh, access for veterans and first responders to be able to attend psychedelic assisted therapy retreats to treat issues like mild TBI, post-traumatic stress disorder, uh, depression, sometimes addiction at, at a very low level. Jay Kopelman: Um, and, and so we've, we've been doing this for a little more than a year now and have provided 250 plus scholarships to veterans and first responders to be able to access. These retreats and these, these lifesaving medicines. Um, we're also partnered, uh, you may or may not know with Melissa at Psychedelic Medicine Coalition to help advance education and policy, specifically the innovative, uh, therapy Centers of Excellence Act [00:04:00] that Melissa has worked for a number of years on now to bring to both Houses of Congress. Joe Moore: Thank you for that. Um, so let's chat a little bit about what this event was that just, uh, went down, uh, what, what was it two weeks ago at this point? Melissa Lavasani: Yeah. Yeah. It's called For Veteran Society and it's all, um, there's a lot of dialogue on Capitol Hill about veterans healthcare and psychedelics, but where I've been frustrated is that, you know, it was just a lot of. Melissa Lavasani: Talk about what the problems are and not a lot of talk about like how we actually propel things forward. Um, so it, at that event, I thought it was really important and we had three members of Congress there, um, Morgan Latrell, who has been a champion from day one and his time in Congress, um, having gone through the experience himself, um, [00:05:00] at Mission within, um, and then the two chairs of the psychedelic caucus, uh, Lou Correa and Jack Bergman. Melissa Lavasani: And we really got down to the nitty gritty of like w like why this has taken so long and you know, what is actually happening right now? What are the possibilities and what the roadblocks are. And it was, I thought it was a great conversation. Um, we had an interesting kind of dynamic with Latres is like a very passionate about this issue in particular. Melissa Lavasani: Um, I think it was, I think it was really. A great event. And, you know, two days later, Jack Bergman introduced his new bill for the va. Um, so it was kind of like the precursor to that bill getting introduced. And we're just excited for more and more conversations about how the government can gently guide this issue to success. Joe Moore: Hmm. Yeah. [00:06:00] That's fantastic. Um, yeah, I was a little bummed I couldn't make it, but next time, I hope. But I've heard a lot of good things and, um, it's, it sounded like there was some really important messages in, in terms of like feedback from legislators. Yeah. Yeah. Could you speak to that? Melissa Lavasani: Yeah, I mean, I think when, uh, representative Latrell was speaking, he really impressed on us a couple things. Melissa Lavasani: Um, first is that, you know, they really kind of need the advocates to. Coordinate, collaborate and come up with like a, a strategic plan, you know, without public education. Um, talking to members of Congress about this issue is, is really difficult. You know, like PMC is just one organization. We're very little mission within, very little, um, you know, we're all like, kind of new in navigating, um, this not so new issue, but new to Washington DC [00:07:00] issue. Melissa Lavasani: Um, without that public education as a baseline, uh, it's, it's, you have to spend a lot of time educating members of Congress. You know, that's like one of our things is, you know, we have to, we don't wanna tell Congress what direction to go to. We wanna provide them the information so they understand it very intimately and know how to navigate through things. Melissa Lavasani: Um, and secondly. Um, he got pretty frank with us and said, you know, we've got one cha one chance at this issue. And it's like, that's, that's kind of been like my talking point since I started. PMC is like, you have a very limited window, um, when these kind of issues pop up and they're new and they're fresh and you have a lot of the veteran community coming out and talking about it. Melissa Lavasani: And there's a lot of energy there. But now is the time to really move forward, um, with some real legislation that can be impactful. Um, but, you know, we've gotta [00:08:00] be careful. We, we forget, I think sometimes those of us who are in the ecosystem forget that our level of knowledge about these medicines and a lot of us have firsthand experience, um, with these drugs and, and our own healing journeys is, um, we forget that there is a public out there that doesn't have the level of knowledge that we all have. Melissa Lavasani: And, um. We gotta make sure that we're sticking to the right elements of, of, of what needs to happen. We need to be sure that our talking points are on track and we're not getting sideways about anything and going down roads that we don't need to talk about. It's why, um, you know, PMC is very focused on, um, moving forward veteran legislation right now. Melissa Lavasani: Not because we're a veteran organization, but because we're, we see this long-term policy track here. Um, we know where we want to get [00:09:00] to, um. Um, and watching other healthcare issues kind of come up and then go through the VA healthcare system, I think it's a really unique opportunity, um, to utilize the VA as this closed system, the biggest healthcare system in the country to evaluate, uh, how psychedelics operate within systems like that. Melissa Lavasani: And, you know, before they get into, um, other healthcare systems. What do we need to fix? What do we need to pay attention to? What's something that we're paying too much attention to that doesn't necessarily need that much attention? So it's, um, it's a real opportunity to look at psychedelic medicines within a healthcare system and obviously continue to gather the data. Melissa Lavasani: Um, Bergman's Bill emerging, uh, expanding veteran access to emerging treatments. Um, not only mandates the research, it gives the VA authority for this, uh, for running trials and, and creating programs around psychedelic medicines. But also, [00:10:00] one of the great things about it, I think, is it provides an on-ramp for veterans that don't necessarily qualify for clinical trials. Melissa Lavasani: You know, I think that's one of the biggest criticisms of clinical trials is like you're cre you're creating a vacuum for people and people don't live in a vacuum. So we don't necessarily know what psychedelics are gonna look like in real life. Um, but with this expanding veteran access bill that Bergman introduced, it provides the VA an opportunity to provide this access under. Melissa Lavasani: Um, in a, in a safe container with medical supervision while collecting data, um, while ensuring that the veteran that is going through this process has the support systems that it needs. So, um, you know, I think that there's a really unique opportunity here, and like Latrell said, like, we've got one shot at this. Melissa Lavasani: We have people's attention in Congress. Um, now's the time to start acting, and let's be really considerate and thoughtful about what we're doing with it. Joe Moore: Thanks for that, Melissa and Jay, how, [00:11:00] anything to add there on kind of your takeaways from the this, uh, last visit in dc? Jay Kopelman: Yeah, I, I think that Melissa highlighted it really well and there, there were a couple other things that I, I think, you know, you could kind of tie it all together with some other issues that we face in this country, uh, and that. Jay Kopelman: Uh, representative Correa brought up as well, but one of the things I wanted to go back and say is that veterans have kind of led this movement already, right? So, so it's a, it's a good jumping off point, right? That it's something people from both sides of the aisle, from any community in America can get behind. Jay Kopelman: You know, if you think about it, uh, in World War ii, you know, we had a million people serving our population was like, not even 200 million, but now [00:12:00] we have a population of 330 million, and at any given time there might be a million people in uniform, including the Reserve and the National Guard. So it's, it, it's an easy thing to get behind this small part of the population that is willing to sign that contract. Jay Kopelman: Where you are saying, yeah, I'm going to defend my country, possibly at the risk of my l my own life. So that's the first thing. The other thing is that the VA being a closed health system, and they don't have shareholders to answer to, they can take some risks, they can be innovative and be forward thinking in the ways that some other healthcare systems can't. Jay Kopelman: And so they have a perfect opportunity to show that they truly care for their veterans, which don't, I'm not saying they don't, but this would be an [00:13:00] opportunity to show that carrot at a whole different level. Uh, it would allow them to innovate and be a leader in something as, uh, as our friend Jim Hancock will say, you know. Jay Kopelman: When he went to the Naval Academy, they had the world's best shipbuilding program. Why doesn't the VA have the world's best care program for things like TBI and PTSD, which affects, you know, 40 something percent of all veterans, right? So, so there's, there's an opportunity here for the VA to lead from the front. Jay Kopelman: Um, the, these medicines provide, you know, reasonably lasting care where it's kind of a one and done. Whereas with the current systems, the, you know, and, and [00:14:00] again, not to denigrate the VA in any way, they're doing the best job they can with the tools in their toolbox, right? But maybe it's time for a trip to Home Depot. Jay Kopelman: Let's get some new tools. And have some new ways of fixing what's broken, which is really the way of doing things. It's not, veterans aren't broken, we are who we are. Um, but it's a, it's a way to fix what isn't working. So I, I think that, you know, given there's tremendous veteran homelessness still, you know, addiction issues, all these things that do translate to the population at large are things that can be worked on in this one system, the va that can then be shown to have efficacy, have good data, have [00:15:00] good outcomes, and, and take it to the population at large. Joe Moore: Mm-hmm. Brilliant. Thanks for that. And so there was another thing I wanted to pivot to, which is some of the recent press. So we've, um, seen a little bit of press around some, um, in one instance, some bad behavior in Mexico that a FI put out Americans thrive again, put out. And then another case there was a, a recent fatality. Joe Moore: And I think, um, both are tragic. Like we shouldn't be having to deal with this at this point. Um, but there's a lot of things that got us here. Um, it's not necessarily the operator's fault entirely, um, or even at all, honestly, like some medical interventions just carry a lot of risk. Like think, think about like, uh, how risky bypass surgery was in the nineties, right? Joe Moore: Like people were dying a lot from medical interventions and um, you know, this is a major intervention, uh, ibogaine [00:16:00] and also a lot of promise. To help people quite a bit. Um, but as of right now, there's, there's risk. And part of that risk, in my opinion, comes from the inability of organizations to necessarily collaborate. Joe Moore: Like there's no kind of convening body, sitting in the middle, allowing, um, for, and facilitating really good data sharing and learnings. Um, and I don't, I don't necessarily see an organization stepping up and being the, um, the convener for that kind of work. I've heard rumors that something's gonna happen there, and I'm, I'm hopeful I'll always wanna share my opinion on that. Joe Moore: But yeah. I don't know. Jay, from your perspective, is there anything you want to kind of speak to about, uh, these two recent incidents that Americans for Iboga kind of publicized recently? Jay Kopelman: Yeah, so I, I'll echo your sentiment, of course, that these are tragic incidents. Um, and I, [00:17:00] I think that at least in the case of the death at Ambio, AMBIO has done a very good job of talking about it, right? Jay Kopelman: They've been very honest with the information that they have. And like you said, there are risks inherent to these medicines, and it's like anything else in medicine, there are going to be risks. You know, when I went through, uh, when I, when I went through chemo, you know, there were, there are risks. You know, you don't feel well, you get sick. Jay Kopelman: Um, and, and it. There are processes in place to counter that when it happens. And there are processes and, and procedures and safety protocols in place when caring for somebody going through an ibogaine [00:18:00] journey. Uh, when I did it, we had EKG echocardiogram. You're on a heart monitor the entire time they push magnesium via iv. Jay Kopelman: You have to provide a urinalysis sample to make sure that there is nothing in your system that is going to potentially harm you. During the ibogaine, they have, uh, a cardiologist who is monitoring the heart monitors throughout the ibogaine experience. So the, the safety protocols are there. I think it's, I think it's just a matter of. Jay Kopelman: Standardizing them across all, all providers, right? Like, that would be a good thing if people would talk to one another. Um, as, as in any system, right? You've gotta have [00:19:00] some collaboration. You've gotta have standardization, you know, so, you know, they're not called standard operating procedures for nothing. Jay Kopelman: That means that in a, you know, in a given environment, everybody does things the same way. It's true in Navy and Marine Corps, air Force, army Aviation, they have standard operating procedures for every single aircraft. So if you fly, let's say the F 35 now, right? Because it's flown by the Navy, the Marine Corps, and the Air Force. Jay Kopelman: The, the emergency procedures in that airplane are standardized across all three services, so you should have the same, or, you know, with within a couple of different words, the same procedures and processes [00:20:00] across all the providers, right? Like maybe in one document you're gonna change, happy to glad and small dog to puppy, but it's still pretty much the, the same thing. Jay Kopelman: And as a service that provides scholarships to people to go access these medicines and go to these retreats, you know, my criteria is that the, this provider has to be safe. Number one, safety's paramount. It's always gotta be very safe. It should, it has to be effective. And you know, once you have those two things in place, then I have a comfort level saying, okay, yeah, we'll work with this provider. Jay Kopelman: But until those standardized processes are in place, you'll probably see these one-off things. I mean, some providers have been doing this longer than others and have [00:21:00] really figured out, you know, they've, they've cracked the code and, you know, sharing that across the spectrum would be good. Um, but just when these things happen, having a clearing house, right, where everybody can come together and talk about it, you know, like once the facts are known because. Jay Kopelman: To my knowledge, we still don't know all the facts. Like as, you know, as horrible as this is, you still have to talk about like an, has an autopsy been performed? What was found in the patient's system? You know, there, there are things there that we don't know. So we need to, we need to know that before we can start saying, okay, well this is how we can fix that, because we just don't know. Jay Kopelman: And, you know, to their credit, you know, Amio has always been safe to, to the, to the best of my knowledge. You know, I, [00:22:00] I haven't been to Ambio myself, but people that I have worked with have been there. They have observed, they have seen the process. They believe it's safe, and I trust their opinion because they've seen it elsewhere as well. Jay Kopelman: So yeah, having, having that one place where we can all come together when this happens, it, it's almost like it should be mandatory. In the military when there's a training accident, we, you know, we would have to have what's called a safety standout. And you don't do that again for a little while until you figure out, okay, how are we going to mitigate that happening again? Jay Kopelman: Believe me, you can go overboard and we don't want to do that. Like, we don't wanna just stop all care, but maybe stop detox for a week and then come back to it. [00:23:00] Joe Moore: Yeah. A dream would be, let's get like the, I don't know, 10, 20 most popular, uh, or well-known operators together somewhere and just do like a three day debrief. Joe Moore: Hey, everybody, like, here's what we see. Let's work on this together. You know how normal medicine works. And this is, it's hard because this is not necessarily, um, something people feel safe about in America talking about 'cause it's illicit here. Um, I don't understand necessarily how the operations, uh, relate to each other in Mexico, but I think that's something to like the public should dig into. Joe Moore: Like, what, what is this? And I, I'll start digging into that. Um, I, I asked a question recently of somebody like, is there some sort of like back channel signal everybody's using and there's no clear Yes. You know? Um, I think it would be good. That's just a [00:24:00] start, you know, that's like, okay, we can actually kind of say hi and watch out for this to each other. Jay Kopelman: It's not like we don't all know one another, right? Joe Moore: Yes. Jay Kopelman: Like at least three operators we're represented. At the Aspen Ibogaine meeting. So like that could be, and I think there was a panel kind of loosely related to this during Aspen Ibogaine meeting, but Joe Moore: mm-hmm. Jay Kopelman: It, you know, have a breakout where the operators can go sit down and kind of compare notes. Joe Moore: Right. Yeah. Melissa, do you have any, uh, comments on this thread here? And I, I put you on mute if you didn't see that. Um, Melissa Lavasani: all right, I'm off mute. Um, yeah, I think that Jay's hits the nail on the head with the collaboration thing. Um, I think that it's just a [00:25:00] problem across the entire ecosystem, and I think that's just a product of us being relatively new and upcoming field. Melissa Lavasani: Um, uh, it's a product of, you know. Our fundraising community is really small, so organizations feel like they are competing for the same dollars, even though their, their goals are all the same, they have different functions. Um, I think with time, I mean, let's be honest, like if we don't start collaborating and, and the federal government's moving forward, the federal government's gonna coordinate for us. Melissa Lavasani: And not, that might not necessarily be a bad thing, but, you know, we understand this issue to a whole other level that the federal government doesn't, and they're not required to understand it deeply. They just need to know how to really move forward with it the proper way. Um, but I think that it. It's really essential [00:26:00] that we all have this come together moment here so we can avoid things. Melissa Lavasani: Uh, I mean, no one's gonna die from bad advocacy. So like I've, I have a bit of an easier job. Um, but it can a, a absolutely stall efforts, um, to move things forward in Washington DC when, um, one group is saying one thing, another group is saying another thing, like, we're not quite at a point yet where we can have multiple lines of conversation and multiple things moving forward. Melissa Lavasani: Um, you know, for PMC, it's like, just let's get the first thing across the finish line. And we think that is, um, veteran healthcare. And, um, I know there's plenty of other groups out there that, that want the same thing. So, you know, I always, the reason why I put on the Federal Summit last year was I kind of hit my breaking point with a lack of collaboration and I wanted to just bring everyone in the same room and say like, all right, here are the things that we need to talk about. Melissa Lavasani: And I think the goal for this year is, um. To bring people in the same room and say, we talked about [00:27:00] we scratched the surface last year and this is where we need to really put our efforts into. And this is where the opportunities are. Um, I think that is going to, that's going to show the federal government if we can organize ourselves, that they need to take this issue really seriously. Melissa Lavasani: Um, I don't think we've done a great job at that thus far, but I think there's still plenty of time for us to get it together. Um, and I'm hoping with these two, uh, VA bills that are in the house right now and Senate is, is putting together their version of these two bills, um, so that they can move in tandem with each other. Melissa Lavasani: I think that, you know, there's an opportunity here for. Us to show the federal government as an ecosystem, Hey, we, we are so much further ahead and you know, this is what we've organized and here's how we can help you, um, that would make them buy into this issue a bit more and potentially move things forward faster. Melissa Lavasani: Uh, at this point in time, it's, I think that, [00:28:00] you know, psychedelics aren't necessarily the taboo thing that they, they used to be, but there's certainly places that need attention. Um, there's certainly conversations that need to be had, and like I said, like PMC is just one organization that can do this. Um, we can certainly organize and drive forward collaboration, but I, like we alone, cannot cover all this ground and we need the subject matter experts to collaborate with us so we can, you know, once we get in the door, we wanna bring the experts in to talk to these officials about it. Melissa Lavasani: So I. I, I really want listeners to really think about us as a convener of sorts when it comes to federal policy. Um, and you know, I think when, like for example, in the early eighties, a lot of people have made comparisons to the issue of psychedelics to the issue of AIDS research and how you have in a subject matter that's like extremely taboo and a patient population that the government [00:29:00] quite honestly didn't really care about in the early eighties. Melissa Lavasani: But what they did as an ecosystem is really organized themselves, get very clear on what they wanted the federal government to do. And within a matter of a couple years, uh, AIDS research funding was a thing that was happening. And what that, what that did was that ripple effect turned that into basically finding new therapies for something that we thought was a death, death sentence before. Melissa Lavasani: So I think. We just need to look at things in the past that have been really successful, um, and, and try to take the lessons from all of these issues and, and move forward with psychedelics. Joe Moore: Love that. And yes, we always need to be figuring out efficient approaches and where it has been successful in the past is often, um, an opportunity to mimic and, and potentially improve on that. Melissa Lavasani: Yeah. Jay Kopelman: One, one thing I think it's important to add to this part of the conversation is that, [00:30:00] you know, Melissa pointed out there are a number of organizations that are essentially doing the same thing. Jay Kopelman: Um, you know, I like to think we do things a little bit differently at Mission within Foundation in that we don't target any one specific type of service member. We, we work with all veterans. We work with first responders, but. What that leads to is that there are, as far as I've seen, nothing but good intentioned people in this space. Jay Kopelman: You know, people who really care about their patient population, they care about healing, they are trying to do a good job, and more importantly, they're trying to do good. Right? It, it, I think they all see the benefit down the road that this has, [00:31:00] pardon me, not just for veterans, but for society as a whole. Jay Kopelman: And, and ultimately that's where I would like to see this go. You know, I, I would love to see the VA take this. Take up this mantle and, and run with it and provide great data, great outcomes. You know, we are doing some data collection ourselves at Mission within foundation, albeit anecdotal based on surveys given before and after retreats. Jay Kopelman: But we're also working with, uh, Greg Fonzo down at UT Austin on a brain study he's doing that will have 40 patients in it when it's all said and done. And I think we have two more guys to put through that. Uh, and then we'll hit the 40. So there, there's a lot of good here that's being done by some really, really good people who've been doing this for a long time [00:32:00] and want to want nothing more than to, to see this. Jay Kopelman: Come to, come full circle so that we can take care of many, many, many people. Um, you know, like I say, I, I wanna work myself out of a job here. I, I just, I would love to see this happen and then I, you know, I don't have to send guys to Mexico to do this. They can go to their local VA and get the care that they need. Jay Kopelman: Um, but one thing that I don't think we've touched on yet, or regarding that is that the VA isn't designed for that. So it's gonna be a pretty big lift to get the right types of providers into the va with the knowledge, right, with the institutional knowledge of how this should be done, what is safe, what is effective, um, and then it, it's not just providing these medicines to [00:33:00] people and sending them home. Jay Kopelman: You don't just do that, you've gotta have the right therapists on the backend who can provide the integration coaching to the folks who are receiving these medicines. And I'm not just talking, I bga, even with MDMA and psilocybin, you should have a proper period of integration. It helps you to understand how this is going to affect you, what it, what the experience really meant, you know, because it's very difficult sometimes to just interpret it on your own. Jay Kopelman: And so what the experience was and what it meant to you. And, and so it will take some time to spin all that up. But once it's, once it's in place, you know, the sky's the limit. I think. Joe Moore: Kinda curious Jay, about what's, what's going on with Ibogaine at the federal level. Is there anything at VA right now? [00:34:00] Jay Kopelman: At the va? No, not with ibogaine. And, you know, uh, we, we send people specifically for IBOGAINE and five MEO, right? And, and so that, that doesn't preclude my interest in seeing this legislation passed, right? Jay Kopelman: Because it, it will start with something like MDMA or psilocybin, but ultimately it could grow to iboga, right? It the think about the cost savings at, at the va, even with psilocybin, right? Where you could potentially treat somebody with a very inexpensive dose of psilocybin or, or iboga one time, and then you, you don't have to treat them again. Jay Kopelman: Now, if I were, uh, you know, a VA therapist who's not trained in psychedelic trauma therapy. I might be worried [00:35:00] about job security, but it's like with anything, right? Like ultimately it will open pathways for new people to get that training or the existing people to get that training and, and stay on and do that work. Jay Kopelman: Um, which only adds another arrow to their quiver as far as I'm concerned, because this is coming and we're gonna need the people. It's just like ai, right? Like ai, yeah. Some people are gonna lose some jobs initially, and that's unfortunate. But productivity ultimately across all industries will increase and new jobs will be created as a result of that. Jay Kopelman: I mean, I was watching Squawk Box one morning. They were talking about the AI revolution and how there's gonna be a need for 500,000 electricians to. Build these systems that are going to work with the AI [00:36:00] supercomputers and, and so, Joe Moore: mm-hmm. Jay Kopelman: Where, where an opportunity may be lost. I think several more can be gained going forward. Melissa Lavasani: And just to add on what Jay just said there, there's nothing specific going on with Ibogaine at, at the va, but I think this administration is, is taking a real look at addiction in particular. Uh, they just launched, uh, a new initiative, uh, that's really centered on addiction treatments called the Great American Recovery. Melissa Lavasani: And, um, they're dedicating a hundred million dollars towards treating addiction as like a chronic treatable disease and not necessarily a law enforcement issue. So, um, in that initiative there will be federal grant programs for prevention and treatment and recovery. And, um, while this isn't just for psychedelic medicines, uh, I think it's a really great opportunity for the discussion of psychedelics to get elevated to the White House. Melissa Lavasani: Um, [00:37:00] there's also, previous to this announcement last week from the White House, there's been a hundred million dollars that was dedicated at, um, at ARPA h, which is. The advanced research projects, uh, agency for healthcare, um, and that is kind of an agency that's really focused on forward looking, um, treatments and technologies, uh, for, um, a, a whole slew of. Melissa Lavasani: Of issues, but this a hundred million dollars is dedicated to mental health and addiction. So there's a lot of opportunity there as well. So we, while I think, you know, some people are talking about, oh, we need a executive order on Iboga, it's like, well, you know, the, the president is thinking, um, about, you know, what issues can land with his, uh, voting block. Melissa Lavasani: And I think it's, I don't think we necessarily need a specific executive order on Iboga to call this a success. It's like, let's look at what, [00:38:00] um, what's just been announced from the White House. They're, they're all in on. Thinking creatively and finding, uh, new solutions for this. And this is kind of, this aligns with, um, HHS secretaries, uh, Robert F. Melissa Lavasani: Kennedy Junior's goals when he took on this, this role of Health Secretary. Um, addiction has been a discussion that, you know, he has personal, um, a personal tie to from his own experience. And, um, I think when this administration started, there was so much like fervor around the, the dialogue of like, everyone's talking about psychedelics. Melissa Lavasani: It was Secretary Kennedy, it was, uh, secretary Collins at the va. It was FDA Commissioner Marty Macari. And I think that there's like a lot of undue frustration within folks 'cause um, you don't necessarily snap your fingers and change happens in Washington dc This is not the city for that. And it's intentionally designed to move slow so that we can avoid really big mistakes. Melissa Lavasani: Um. [00:39:00] I think we're a year into this administration and these two announcements are, are pretty huge considering, um, you know, the, we, there are known people within domestic policy council that don't, aren't necessarily supportive of psychedelic medicine. So there's a really amazing progress here, and frustrating as it might be to, um, just be waiting for this administration to make some major move. Melissa Lavasani: I think they are making major moves like for Washington, DC These, these are major moves and we just gotta figure out how we can, um, take these initiatives and apply them to the issue of psychedelic medicines. Joe Moore: Thanks, Melissa. Um, yeah, it is, it is interesting like the amount of fervor there was at the beginning. You know, we had, uh. Kind of one of my old lawyers, Matt Zorn, jumped in with the administration. Right. And, um, you know, it was, uh, really cool to [00:40:00] see and hopeful how much energy was going on. It's been a little quiet, kind of feels like a black box a little bit, but I, you know, there was, Melissa Lavasani: that's on me. Melissa Lavasani: Maybe I, we need to be more out in public about like, what's actually happening, because I feel like, like day in and day out, it's just been, you gotta just mm-hmm. Like have that constant beat with the government. Mm-hmm. And, um, it's, it's, it's not the photo ops on the hill, it's the conversations that you have. Melissa Lavasani: It's the dinner parties you go to, it's the fundraisers you attend, you know? Mm-hmm. That's why I, I kind of have to like toot my own horn with PCs. Like, we need to be present here at, at not only on the Hill, not only at the White House, but kind of in the ecosystem of Washington DC itself. There's, it's, there are like power players here. Melissa Lavasani: There are people that are connected that can get things done, like. I mean, the other last week we had a big snow storm. I walked over to my friend's house, um, to have like a little fire sesh with them and our kids, and his next door neighbor came over. He was a member of Congress. I talked about the VA bills, like [00:41:00] we're reaching out to his office now, um, to get them, um, up to speed and hopefully get their co-sponsorship for, uh, the two VA bills. Melissa Lavasani: So, I mean, it, the little conversations you have here are just as important as the big ones with the photo ops. So, um, it, it's, it's really like, you know, building up that momentum and, and finding that time where you can really strike and make something happen. Joe Moore: Mm-hmm. Yeah. Jay, anything to add there? Jay Kopelman: Yeah, I was just gonna say that, you know, I, I, I think the fervor is still there, right? Jay Kopelman: But real life happens. Melissa Lavasani: Yes, Jay Kopelman: yes. And gets in the way, right? So, Melissa Lavasani: yeah, Jay Kopelman: I, I can't imagine how many issues. Secretary Kennedy has every day much less the president. Like there's so many things that they are dealing with on a daily basis, right? It, we, we just have to work to be the squeaky wheel in, in the right way, right. Jay Kopelman: [00:42:00] With the, with the right information at the right time. Like just inundating one of these organizations with noise, it's then it be with Informa, it just becomes noise, right? It it, it doesn't help. So when we have things to say that are meaningful and impactful, we do, and Melissa does an amazing job of that. Jay Kopelman: But, you know, it, it takes time. You know, it's, you know, we're not, this is, this is like turning an aircraft carrier, not a ski boat. Melissa Lavasani: Yeah, Joe Moore: yeah, absolutely. Um, and. It's, it's understandably frustrating, I think for the public and the psychedelic public in particular because we see all this hope, you know, we continue to get frustrated at politics. It's nothing new, right? Um, and we, we wanna see more people get well immediately. [00:43:00] And I, I kind of, Jay from the veteran perspective, I do love the kind of loud voices like, you're making me go to Mexico for this. Joe Moore: I did that and you're making me leave the country for the thing that's gonna fix me. Like, no way. And barely a recognition that this is a valid treatment. You know, like, you know, that is complicated given how medicine is structured here domestically. But it's also, let's face the facts, like the drug war kind of prevented us from being able to do this research in the first place. Joe Moore: You know? Thanks Nixon. And like, how do we actually kind of correct course and say like, we need to spend appropriately on science here so we can heal our own people, including veterans and everybody really. It's a, it's a dire situation out there. Jay Kopelman: Yeah. It, it really is. Um, you know, we were talking briefly about addicts, right? Jay Kopelman: And you know, it's not sexy. People think of addicts as people who are weak-minded, [00:44:00] right? They don't have any self-control. Um, but, but look at, look at the opioid crisis, right? That Brian Hubbard was fighting against in Kentucky for all those years. That that was something that was given to the patient by a doctor that they then became dependent on, and a lot of people died from that. Jay Kopelman: And, and so you, you know, it's, I I don't think it's fair to just put all addicts in a box. Just like it's not fair to put all veterans in a box. Just like it's not fair for doctors, put all their patients in a box. We're individuals. We, we have individual needs. Our, our health is very individual. Like, I, I don't think I should be put in the same box as every other 66-year-old that my doctor sees. Jay Kopelman: It's not fair. [00:45:00] You know, if you, if you took my high school classmates and put us all in a photo, we're all gonna have different needs, right? Like, some look like they're 76, not 66. Some look like they're 56. Not like they're, we, we do things differently. We live our lives differently. And the same is true of addicts. Jay Kopelman: They come to addiction from different places. Not everybody decides they want to just try heroin at a party, and all of a sudden they're addicted. It happens in, in different ways, you know, and the whole fentanyl thing has been so daggum nefarious, right? You know, pushing fentanyl into marijuana. Jay Kopelman: Somebody's smoking a joint and all of a sudden they're addicted to fentanyl or they die. Melissa Lavasani: I think we're having a, Jay Kopelman: it's, it's just not fair to, to say everybody in this pot is the same, or everybody in this one is the same. We have [00:46:00] to look at it differently. Joe Moore: Yeah. I like to zoom one level out and kind of talk about, um, just how hurt we are as a country, as a world really, but as a country specifically, and how many people are out of work for so many. Joe Moore: Difficult reasons and away from their families for so many kind of tragic reasons. And if we can get people back to their families and back to work, a lot of these things start to self-correct, but we have to like have those interventions where we can heal folks and, and get them back. Um, yeah. And you know, everything from trauma, uh, in childhood, you know, adulthood, combat, whatever it is. Joe Moore: Like these things can put people on the sidelines. And Jay, to your point, like you get knee surgery and all of a sudden you're, you know, two years later you're on the hunt for Fentanyl daily. You know, that's tough. It's really tough. Carl Hart does a good job talking about this kind of addiction pipeline and [00:47:00] a few others do as well. Joe Moore: But it's just, you know, kind of putting it in a moral failure bucket. It's not great. I was chatting with somebody about, um, veterans, it's like you come back and you're like, what's gonna make me feel okay right now? And it's not always alcohol. Um, like this is the first thing that made me feel okay, because there's not great treatments and there's, there's a lot of improvements in this kind of like bringing people back from the field that needs to happen. Joe Moore: In my opinion. I, it seems to be shared by a lot of people, but yeah, there's, it's, it's, IGA is gonna be great. It's gonna be really important. I really can't wait for it to be at scale appropriately, but there's a lot of other things we need to fix too, um, so that we can just, you know, not have so many people we need to, you know, spend so much money healing. Joe Moore: Mm-hmm. Jay Kopelman: Yeah. You ahead with that. We don't need the president to sign an executive order to automatically legalize Ibogaine. Right. But it would be nice if he would reschedule it so that [00:48:00] then then researchers could do this research on a larger scale. You know, we could, we could now get some real data that would show the efficacy. Jay Kopelman: And it could be done in a safe environment, you know? And, and so that would be, do Joe Moore: you have any kind of figures, like, like, I've been talking about this for a while, Jay. Like, does it drop the cost a lot of doing research when we deschedule things? Jay Kopelman: I, I would imagine so, because it'll drop the cost of accessing the medicines that are being researched. Jay Kopelman: Right? You, you would have buy-in from more organizations. You know, you might even have a pharma company that comes into this, you know, look at j and j with the ketamine, right? They have, they have a nasal spray version of ketamine that's doing very well. I mean, it's probably their, their biggest revenue [00:49:00] provider for them right now. Jay Kopelman: And, and so. You know, you, it would certainly help and I think, I think it would lower costs of research to have something rescheduled rather than being schedule one. You know it, people are afraid to take chances when you're talking about Schedule one Melissa Lavasani: labs or they just don't have the money to research things that are on Schedule one. Melissa Lavasani: 'cause there's so much in an incredible amount of red tape that you have to go through and, and your facility has to be a certain way and how you contain those, uh, medicines. Oh, researching has to be in a specific container and it's just very cumbersome to research schedule one drugs. So absolutely the cost would go down. Melissa Lavasani: Um, but Joe Moore: yeah, absolutely. Less safes. Melissa Lavasani: Yeah. Joe Moore: Yes. Less uh, Melissa Lavasani: right. Joe Moore: Locked. Yeah. Um, it'll be really interesting when that happens. I'm gonna hold out faith. That we can see some [00:50:00] movement here. Um, because yeah, like why make healing more expensive than it needs to be? I think like that's potentially a protectionist move. Joe Moore: Like, I'm not, I'm not here yet, but, um, look at AbbVie's, uh, acquisition of the Gilgamesh ip. Mm-hmm. Like that's a really interesting move. I think it was $1.2 billion. Mm-hmm. So they're gonna wanna protect that investment. Um, and it's likely going to be an approved medication. Like, I don't, I don't see a world in which it's not an approved medication. Joe Moore: Um, you know, I don't know a timeline, I would say Jay Kopelman: yeah. Joe Moore: Less than six years, just given how much cash they've got. But who knows, like, I haven't followed it too closely. So, and that's an I bga derivative to be clear, everybody, um mm-hmm. If you're not, um, in, in the loop on that, which is hopeful, you know? Joe Moore: Mm-hmm. But I don't know what the efficacy is gonna be with that compared to Ibogaine and then we have to talk about the kind of proprietary molecule stuff. Um, there's like a whole bunch of things that are gonna go on here, and this is one of the reasons why I'm excited about. Federal involvement [00:51:00] because we might actually be able to have some sort of centralized manufacturer, um, or at least the VA could license three or four generic manufacturers per for instance, and that way prices aren't gonna be, you know, eight grand a dose or whatever. Joe Moore: You know, it's, Jay Kopelman: well, I think it's a very exciting time in the space. You know, I, I think that there's the opportunity for innovation. There is the opportunity for collaboration. There's the opportunity for, you know, long-term healing at a very low cost. You know, that we, we have the highest healthcare cost per capita in the world right here in the us. Jay Kopelman: And, and yet we are not the number one health system in the world. So to me, that doesn't add up. So we need to figure out a way to start. Bringing costs down for a lot of people and [00:52:00] at the same time increasing, increasing outcomes. Joe Moore: Absolutely. Yeah. There's a lot of possible outcome improvements here and, and you know, everything from relapse rates, like we hear often about people leaving a clinic and they go and overdose when they get home. Tragically, too common. I think there's everything from, you know, I'm Jay, I'm involved in an organization called the Psychedelics and Pain Association. Joe Moore: We look at chronic pain very seriously, and IGA is something we are really interested in. And if. We could have better, you know, research, there better outcome measures there. Um, you know, perhaps we can have less people on opioids to begin with from chronic pain conditions. Um, Jay Kopelman: yeah, I, I might be due for another Ibogaine journey then, because I deal with chronic pain from Jiujitsu, but, Joe Moore: oh gosh, let's Jay Kopelman: talk Joe Moore: later. Jay Kopelman: That's self inflicted. Some people would say take a month off, but Melissa Lavasani: yeah, Jay Kopelman: I'm [00:53:00] not, I'm not that smart. Joe Moore: Yeah. Um, but you know, this, uh, yeah, this whole thing is gonna be really interesting to see how it plays out. I'm endlessly hopeful pull because I'm still here. Right. I, I've been at this for almost 10 years now, very publicly, and I think we are seeing a lot of movement. Joe Moore: It's not always what we actually wanna see, but it is movement nonetheless. You know, how many people are writing on this now than there were before? Right. You know, we, we have people in New York Times writing somewhat regularly about psychedelics and. Even international media is covering it. What do we have legalization in Australia somewhat recently for psilocybin and MDMA, Czech Republic. Joe Moore: I think Germany made some moves recently. Mm-hmm. Um, really interesting to see how this is gonna just keep shifting. Um Jay Kopelman: mm-hmm. Joe Moore: And I think there's no way that we're not gonna have prescription psychedelics in three years in the United States. It pro probably more like a [00:54:00] year and a half. I don't know. Do you, are you all taking odds? Melissa Lavasani: Yeah. I mean, I think Jay Kopelman: I, I gotta check Cal sheet, see what they're saying. Melissa Lavasani: I think it's safe to say, I mean, this could even come potentially the end of this year, I think, but definitely by the end of 2027, there's gonna be at least one psychedelic that's FDA approved. Joe Moore: Yeah. Yeah. Melissa Lavasani: If you're not counting Ketamine. Joe Moore: Right. Jay Kopelman: I, I mean, I mean it mm-hmm. It, it doesn't make sense that it. Shouldn't be or wouldn't be. Right. The, we've seen the benefits. Mm-hmm. We know what they are. It's at a very low cost, but you have to keep in mind that these things, they need to be done with the right set setting and container. Right. And, and gotta be able to provide that environment. Jay Kopelman: So, but I would, I would love, like I said, I'd love to work myself out of a job here and see this happen, not just for our veterans, [00:55:00] but for everybody. Joe Moore: Mm-hmm. Um, so Melissa, is there a way people can get involved or follow PMC or how can they support your work at PMC? Melissa Lavasani: Yeah, I mean, follow us in social media. Melissa Lavasani: Um, our two biggest platforms are LinkedIn and Instagram. Um, I'm bringing my newsletter back because I'm realizing, um, you know, there is a big gap in, in kind of like the knowledge of Washington DC just in general. What's happening here, and I think, you know, part of PC's value is that we're, we are plugged into conversations that are being had, um, here in the city. Melissa Lavasani: And, you know, we do get a little insight. Um, and I think that that would really quiet a lot of, you know, the, a lot of noise that, um, exists in the, our ecosystem. If, if people just had some clarity on like, what's actually happening or happening here and what are the opportunities and, [00:56:00] um, where do we need more reinforcement? Melissa Lavasani: Um, and, and also, you know, as we're putting together public education campaign, you know. My, like, if I could get everything I wanted like that, that campaign would be this like multi-stakeholder collaborative effort, right? Where we're covering all the ground that we need to cover. We're talking to the patient groups, we're talking to traditional mental health organizations, we're talking to the medical community, we're talking to the general population. Melissa Lavasani: I think that's like another area that we, we just seem to be, um, lacking some effort in. And, you know, ultimately the veteran story's always super compelling. It pulls on your heartstrings. These are our heroes, um, of our country. Like that, that is, that is meaningful. But a lot of the veteran population is small and we need the, like a, the just.[00:57:00] Melissa Lavasani: Basic American living in middle America, um, understanding what psychedelics are so that in, in, in presenting to them the stories that they can relate to, um, because that's how you activate the public and you activate the public and you get them to see what's happening in these clinical trials, what the data's been saying, what the opportunities are with psychedelics, and then they start calling their members of Congress and saying, Hey, there is this. Melissa Lavasani: Bill sitting in Congress and why haven't you signed onto it? And that political pressure, uh, when used the right way can be really powerful. So, um, I think, you know, now we're at this really amazing moment where we have a good amount of congressional offices that are familiar enough with psychedelics that they're willing to move on it. Melissa Lavasani: Um, there's another larger group, uh, that is familiar with psychedelics and will assist and co-sponsor legislation, but there's still so many offices that we haven't been able to get to just 'cause like we don't have all the time in the world and all the manpower in the world to [00:58:00] do it. But, you know, that is one avenue is like the advocates can speak to the, the lawmakers, the experts speak to the lawmakers, and we not, we want the public engaged in this, you know, ultimately, like that's. Melissa Lavasani: Like the best form of harm reduction is having an informed public. So we are not, they're not seeing these media headlines of like, oh, this miracle cure that, um, saved my family. It's like, yes, that can happen psychedelics. I mean, person speaking personally, psychedelics did save my family. But what you miss out of that story is the incredible amount of work I put into myself and put into my mental health to this day to maintain, um, like myself, my, my own agency and like be the parent that I wanna be and be the spouse that I wanna be. Melissa Lavasani: So, um, we, we need to continue to share these stories and we need to continue to collaborate to get this message out because we're all, we're all in the same boat right now. We all want the same things. We want patients to have safe and [00:59:00] affordable access to psychedelic assisted care. Um, and, uh. We're just in the beginning here, so, um, sign up for our newsletter and we can sign up on our website and then follow us on social media. Melissa Lavasani: And, um, I anticipate more and more events, um, happening with PMC and hopefully we can scale up some of these events to be much more public facing, um, as this issue grows. So, um, I'm really excited about the future and I'm, I've been enjoying this partnership with Mission Within. Jay is such a professional and, and it really shows up when he needs to show up and, um, I look forward to more of that in the future. Joe Moore: Fantastic. And Jay, how can people follow along and support mission within Foundation? Jay Kopelman: Yeah, again, social media is gonna be a good way to do that. So we, we are also pretty heavily engaged on LinkedIn and on Instagram. Um, I do [01:00:00] share, uh, a bit of my own stuff as well. On social media. So we have social media pages for Mission within Foundation, and we have a LinkedIn page for mission within foundation. Jay Kopelman: I have my own profiles on both of those as well where people can follow along. Um, one of the other things you know that would probably help get more attention for this is if the general public was more aware of the numbers of professional athletes who are also now pursuing. I began specifically to help treat their traumatic brain injuries and the chronic traumatic encephalopathy that they've, uh, suffered as a result of their time in professional sports or even college sports. Jay Kopelman: And, you know. I people worship these athletes, and I [01:01:00] think that if more of them, like Robert Gall, were more outspoken about these treatments and the healing properties that they've provided them, that it would get even more attention. Um, I think though what Melissa said, you know, I don't wanna parrot anything she just said because she said it perfectly Right. Jay Kopelman: And I'd just be speaking to hear myself talk. Um, but being collaborative the way that we are with PMC and with Melissa is I think, the way to move the needle on this overall. And like she said, if she could get more groups involved in, in these discussions, it would, it would do wonders for us. Joe Moore: Well, thank you both so much for your hard work out there. I always appreciate it when people are showing up and doing this important, [01:02:00] sometimes boring and tedious, but nevertheless sometimes, sometimes exciting work. And um, so yeah, just thank you both and thank you both for showing up here to psychedelics today to join us and I hope we can continue to support you all in the future. Jay Kopelman: Thank you, Joe. Thank you, Joe. It's a pleasure being with you today and with Melissa, of course, always Melissa Lavasani: appreciate the time and space. Joe Moore: Thanks.  

Time for Sports Graffiti! Mason and Ireland discuss the most improbable sports outcomes. Bergman drops into the studio for a ‘Boys in Blue' report! The Dodgers have re-signed Bullpen arm Evan Phillips! Take a listen to Tom Brady and Logan Paul debating athleticism. Can you bet on anything these days? Learn more about your ad choices. Visit podcastchoices.com/adchoices